Welcoming 2026: A Year of Innovation, Integrity, and Global Connection

As we enter 2026, we reflect on the progress made in 2025, acknowledge the collective achievements of our authors, reviewers, section editors, and partners, and share the new developments that will shape the coming year.

Publication History

Received: 05 December 2025

Accepted: 05 December 2025

Article published online:
02 January 2026

• References

• 1 Campello E, Bucciarelli P, Catalani F, Erba N, Squizzato A, Poli D. Scientific Reviewer Committee. Anticoagulant therapy in pregnant women with mechanical heart valves: Italian Federation of Centers for Diagnosis and Surveillance of the Antithrombotic Therapies (FCSA) position paper. Thromb Haemost 2024; 124 (08) 695-708
• 2 Galliazzo S, Bucciarelli P, Barcellona D. et al. Practical suggestions for an optimal management of vitamin K antagonists: Italian Federation of Centers for the Diagnosis of Thrombotic Disorders and the Surveillance of the Antithrombotic Therapies (FCSA) position paper. Thromb Haemost 2024; 124 (08) 803-809
• 3 Campello E, Cappugi C, Catalani F, Poli D, Bucciarelli P. Management of anticoagulant therapy in athletes and sportspeople: Italian Federation of Centers for Diagnosis and Surveillance of the Antithrombotic Therapies (FCSA) position paper. Thromb Haemost 2025; 125 (11) 1085-1098
• 4 Mauge L, Madar H, Carré J. et al; TITAN group of the French Society of Thrombosis and Haemostasis (SFTH). How to manage venous thromboembolism risk during pregnancy in patients with inherited antithrombin deficiency?. Thromb Haemost 2025; . (e-pub ahead of print)
• 5 Jourdi G, Flaujac C, De Maistre E, Gendron N, Eschwège V, Mauge L. French Society on Thrombosis Haemostasis. Usefulness and limits of DOAC removal agents based on activated charcoal in thrombophilia testing: literature review and expert proposals. Thromb Haemost 2025; . (e-pub ahead of print)
• 6 Wang Y, Guo Y, Qin M. et al; Expert Reviewers. 2024 Chinese expert consensus guidelines on the diagnosis and treatment of atrial fibrillation in the elderly, endorsed by Geriatric Society of Chinese Medical Association (Cardiovascular Group) and Chinese Society of Geriatric Health Medicine (Cardiovascular Branch): executive summary. Thromb Haemost 2024; 124 (10) 897-911
• 7 Ortega-Martorell S, Olier I, Ohlsson M, Lip GYH. TARGET Consortium. TARGET: a major European project aiming to advance the personalised management of atrial fibrillation-related stroke via the development of health virtual twins technology and artificial intelligence. Thromb Haemost 2025; 125 (01) 7-11
• 8 Boriani G, Mei DA, Lip GYH. ARISTOTELES consortium. A European-multicenter network for the implementation of artificial intelligence to manage complexity and comorbidities of atrial fibrillation patients: the ARISTOTELES consortium. Thromb Haemost 2025; 125 (03) 189-193
• 9 Harvey KH, Korompoki E, Harvey ER. et al. Personalized Medicine, Public Health and Patient-Centred Aspects in the Prevention of Stroke in Intracerebral Haemorrhage Survivors with Atrial Fibrillation (PRESTIGE-AF) Project. Thromb Haemost 2025; . (e-pub ahead of print)
• 10 Zarghami M, Rashedi S, Piazza G, Gerhard-Herman MD, Barnes GD, Bikdeli B. Heterogeneity in American and European peripheral artery disease guidelines on non-statin lipid-lowering therapy and rivaroxaban. Thromb Haemost 2025; 125 (09) 821-824
• 11 Chang H-C, Chan Y-H, Kuo L, Chao T-F. Patient care pathways and risk assessments in patients with atrial fibrillation: a comparison of Asian versus non-Asian cohorts. Thromb Haemost 2025; 125 (12) 1173-1180
• 12 Mohr K, Barco S, Neusius T, Konstantinides S. Socioeconomic burden of pulmonary embolism in Europe: shifting priorities and challenges for novel reperfusion strategies. Thromb Haemost 2025; 125 (10) 933-943
• 13 Wada H, Shiraki K, Shimpo H, Miyata T. Evaluation of deficiency and excessive condition of thrombin burst using laboratory tests. Thromb Haemost 2025
• 14 Kolios NG, Barkas F, Ntaios G, Milionis H. Strategic lowering of LDL-cholesterol post ischemic stroke: identifying optimal targets, timing, and therapeutic approaches. Thromb Haemost 2025; (e-pub ahead of print)
• 15 Nagao A, Goto S, Goto S. Antithrombotic therapy in people with hemophilia—a narrative review. Thromb Haemost 2025; 125 (11) 1060-1068
• 16 Lecumberri R, Marcos-Jubilar M, Hermida J, Ruiz-Artacho P. Differences in the outcome of cancer-associated thrombosis depending on cancer type. Thromb Haemost 2025; 125 (11) 1053-1059
• 17 Spagnolo M, Capodanno D. Factor XI inhibitors for myocardial infarction: a safer path to thrombotic protection?. Thromb Haemost 2025; 125 (12) 1169-1172
• 18 Violi F, Cammisotto V, Pignatelli P, Valeriani E. Gut microbiota-platelet axis and thrombosis in advanced chronic liver disease. Thromb Haemost 2025; (e-pub ahead of print)
• 19 Goto S, Goto S. Physical and mechanobiological basis of biological functions of platelets. Thromb Haemost 2025; (e-pub ahead of print)
• 20 Kaiser R, Gold C, Stark K. Recent advances in immunothrombosis and thromboinflammation. Thromb Haemost 2025; 125 (12) 1181-1194
• 21 van Zelm AMH, Fiolet ATL, Hinchliffe RJ, Jansen S, Teraa M, Chan NC. Current evidence and future directions for colchicine in the prevention of atherosclerotic cardiovascular disease. Thromb Haemost 2025; (e-pub ahead of print)
• 22 Pfeferman MB, Rashedi S, Lip GYH. et al. Lipoprotein(a) and venous thromboembolism: association, causality, and medications. Thromb Haemost 2025; 125 (11) 1069-1084
• 23 Zhang Z, Zhou X, Fang X, Zhou X, Cheng Z, Hu Y. Platelet disorders and medication strategies. Thromb Haemost 2025; (e-pub ahead of print)
• 24 Galusko V, Panoulas V, Gorog DA, Vandenbriele C. Stroke in mechanical circulatory supported cardiogenic shock. Thromb Haemost 2025; (e-pub ahead of print)
• 25 de Vecchi AC, Cavarra O, Del Alamo R. et al. Digital twins for predictive modelling of thrombosis and stroke risks: current approaches and future directions. Thromb Haemost 2025; (e-pub ahead of print)